BURP1 Antibody

What is BUBR1 and why is it important in cell cycle research?

BUBR1 (BUB1B) is an essential component of the mitotic checkpoint that ensures proper chromosome segregation during cell division. It functions by delaying anaphase until all chromosomes are properly attached to the mitotic spindle . BUBR1 has two primary checkpoint functions: inhibiting the activity of the anaphase-promoting complex/cyclosome (APC/C) by blocking CDC20 binding to APC/C (independent of its kinase activity), and monitoring kinetochore activities dependent on the kinetochore motor CENPE . BUBR1 is particularly valuable in research on mitotic checkpoints, genomic instability, and cancer, as it may play a role in tumor suppression .

What types of BUBR1 antibodies are available for research applications?

Several types of BUBR1 antibodies are available for research:

Each antibody type offers different advantages depending on your experimental requirements .

How should I select the appropriate BUBR1 antibody for my experiment?

Selection should be based on several factors:

• Application compatibility: Verify the antibody has been validated for your specific application (WB, IF, IHC, etc.)

• Species reactivity: Ensure the antibody recognizes BUBR1 in your model organism

• Epitope location: Consider which domain of BUBR1 you wish to detect (N-terminal, kinase domain, etc.)

• Clonality: Monoclonal antibodies offer higher specificity, while polyclonal antibodies may provide stronger signals

• Citation history: Check if the antibody has been successfully used in published research similar to your experimental design

For mitotic checkpoint studies, antibodies recognizing the N-terminal domain may be particularly relevant as this region is essential for spindle assembly checkpoint function .

What controls should I include when using BUBR1 antibodies in immunoassays?

Proper controls are essential for reliable data interpretation:

• Positive control: Include samples known to express BUBR1 (e.g., mitotically arrested cells)

• Negative control: Use samples where BUBR1 is absent or depleted (e.g., siRNA-treated cells)

• Isotype control: Include an antibody of the same isotype, host species, and subclass but without specificity to BUBR1

• Loading control: For Western blots, use housekeeping proteins (e.g., GAPDH, actin) to normalize expression levels

• Secondary antibody-only control: To detect non-specific binding of the secondary antibody

For in vivo experiments, isotype controls are particularly important as they allow you to differentiate between results observed from primary antibody binding in an antigen-specific manner and results from non-antigen specific effects .

How can I optimize BUBR1 antibody detection in mitotically arrested cells?

Optimization strategies include:

• Timing: Synchronize cells and collect at prometaphase when BUBR1 localizes to kinetochores

• Cell synchronization: Use nocodazole (10μM for 12-16 hours) to arrest cells in mitosis and enhance BUBR1 detection

• Fixation method: For immunofluorescence, use cold methanol fixation to better preserve kinetochore structures

• Antibody concentration: Titrate antibody concentrations to determine optimal signal-to-noise ratio

• Signal amplification: Consider using HRP-polymer detection systems for IHC applications

• Blocking conditions: Optimize blocking conditions to reduce background (typically 5% BSA or 5% normal serum)

Remember that BUBR1 levels decrease as cells progress through mitosis while being continuously synthesized, so timing of sample collection is critical .

How can I investigate BUBR1 post-translational modifications using specific antibodies?

BUBR1 undergoes several post-translational modifications, particularly acetylation and phosphorylation, which regulate its function:

• Acetylation-specific antibodies: Generate or obtain antibodies that specifically recognize K250-acetylated BUBR1

  • Validate specificity using acetylation-deficient mutants (K250R) and acetylation-mimicking mutants (K250Q)

  • Perform IP with anti-BUBR1 followed by Western blot with anti-acetyl-lysine antibodies

• Phosphorylation analysis:

  • Use phospho-specific antibodies to detect BUBR1 phosphorylation states

  • Treat samples with phosphatase inhibitors during lysis to preserve phosphorylation

  • Validate with lambda phosphatase treatment as a negative control

• Experimental design:

  • Compare interphase vs. mitotic cells to detect phase-specific modifications

  • Use synchronization protocols to capture specific cell cycle phases

  • Consider immunoprecipitation followed by mass spectrometry for unbiased PTM profiling

Research has shown that BUBR1 acetylation at K250 is critical for modulating APC/C activity and maintaining the spindle assembly checkpoint .

What approaches can be used to study BUBR1 protein interactions with the mitotic checkpoint complex?

Several methodologies can effectively capture BUBR1 interactions:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate BUBR1 and blot for interacting partners (CDC20, MAD2, BUB3, APC/C components)

  • Use crosslinking agents to stabilize transient interactions

  • Compare interphase vs. mitotic lysates to identify cell cycle-specific interactions

• Proximity ligation assay (PLA):

  • Visualize interactions between BUBR1 and binding partners with spatial resolution

  • Particularly useful for detecting kinetochore-specific interactions

• Domain mapping:

  • Use deletion mutants (e.g., ΔKD, Δ42, EK mutants) to identify domains required for specific protein interactions

  • The N-terminal domain is critical for interactions with CDC20, MAD2, and APC/C

  • Bub3 binding and/or kinetochore localization is required for efficient MCC assembly

• Functional validation:

  • Use wild-type and mutant rescue experiments following endogenous BUBR1 depletion

  • Assess mitotic checkpoint function using time-lapse microscopy or MPM2 staining

Research shows that BUBR1 KEN boxes play two different roles: promoting MCC assembly and blocking substrate recruitment to APC/C .

How can I resolve issues with non-specific binding or high background when using BUBR1 antibodies?

Non-specific binding can be addressed through several approaches:

• Antibody validation:

  • Verify antibody specificity using BUBR1 knockout/knockdown samples

  • Test multiple antibodies targeting different epitopes

• Protocol optimization:

  • Increase blocking time/concentration (5-10% BSA or normal serum)

  • Reduce primary antibody concentration

  • Include 0.1-0.3% Triton X-100 in blocking buffer to reduce non-specific binding

  • Increase washing steps (number and duration)

• Sample preparation:

  • Ensure complete cell lysis for Western blot applications

  • Optimize fixation methods for immunostaining (paraformaldehyde vs. methanol)

  • Use antigen retrieval for IHC applications

• Advanced solutions:

  • Pre-absorb antibody with recombinant protein to remove non-specific antibodies

  • Consider using more specific monoclonal antibodies instead of polyclonal

  • Include additional blocking agents (non-fat milk, fish gelatin)

• Cross-reactivity assessment:

  • Test on multiple cell lines with variable BUBR1 expression levels

  • Use appropriate isotype controls to identify Fc receptor binding

How should I interpret variable BUBR1 expression levels across different cell cycle phases?

BUBR1 expression and localization vary throughout the cell cycle, which must be considered when interpreting results:

• Expression dynamics:

  • BUBR1 levels decrease markedly as cells progress through mitosis

  • BUBR1 is continuously synthesized during mitosis, even during nocodazole arrest

  • Interpret expression levels in context of cell synchronization state

• Localization patterns:

  • In prometaphase, BUBR1 localizes to kinetochores and co-localizes with PCAF

  • As chromosomes align at metaphase, BUBR1 signals at kinetochores decrease

  • Cytoplasmic vs. kinetochore signal should be quantified separately

• Quantification approaches:

  • Normalize BUBR1 signals to kinetochore markers (CENP-C, CREST)

  • Use ratio measurements (kinetochore/cytoplasm) to account for expression variations

  • Compare data across multiple cells at similar cell cycle stages

• Additional considerations:

  • Post-translational modifications (particularly acetylation at K250) affect BUBR1 function and possibly antibody recognition

  • Cell-type specific variations in expression should be documented

  • Treatment with microtubule-targeting drugs will affect BUBR1 localization patterns

How can I design experiments to investigate the role of BUBR1 in tumor suppression?

BUBR1 may function as a tumor suppressor through several mechanisms that can be experimentally investigated:

• Expression analysis in cancer models:

  • Compare BUBR1 expression levels across normal and cancerous tissues using validated antibodies

  • Correlate expression patterns with clinical outcomes and cancer progression markers

  • Analyze post-translational modifications that might alter BUBR1 function in cancer cells

• Functional studies:

  • Use RNAi or CRISPR-Cas9 to deplete BUBR1 in normal cells and assess transformation potential

  • Overexpress wild-type or mutant BUBR1 in cancer cell lines and measure effects on proliferation, migration, and invasion

  • Perform rescue experiments with domain-specific mutants to identify regions critical for tumor suppression

• Chromosome instability assessment:

  • Analyze aneuploidy rates following BUBR1 manipulation

  • Measure mitotic timing and chromosome segregation errors using live-cell imaging

  • Quantify micronuclei formation as a marker of chromosomal instability

• Signaling pathway analysis:

  • Investigate how BUBR1 regulates PLK1 activity in interphase cells

  • Examine the relationship between BUBR1 and centrosome amplification

  • Study BUBR1's role in triggering apoptosis in polyploid cells

What methodologies can be employed to develop and validate novel BUBR1-targeted antibodies with enhanced specificity?

Development of next-generation BUBR1 antibodies can benefit from several advanced approaches:

• Target epitope selection:

  • Focus on highly conserved regions for cross-species reactivity

  • Target unique epitopes to avoid cross-reactivity with related proteins (BUB1)

  • Consider targeting post-translational modification sites for specialized applications

• Advanced antibody generation technologies:

  • Use phage display technologies with specific selection pressures

  • Apply AI-driven approaches like RFdiffusion for antibody design

  • Implement active learning strategies to improve experimental efficiency in antibody development

• Rigorous validation strategies:

  • Test on BUBR1 knockout/knockdown systems as negative controls

  • Validate across multiple applications (WB, IF, IP, Flow cytometry)

  • Confirm specificity with mass spectrometry of immunoprecipitated samples

  • Implement cross-validation with multiple antibodies targeting different epitopes

• Application-specific optimization:

  • Use Plackett-Burman statistical design to determine optimal conditions

  • Develop specialized formulations for challenging applications (frozen tissues, FFPE samples)

  • Characterize binding kinetics using surface plasmon resonance

• Computational approaches:

  • Employ biophysics-informed models to identify and disentangle multiple binding modes

  • Use computational methods to design antibodies with custom specificity profiles

  • Implement inference techniques to predict antibody specificity from experimental data

How might new technologies in antibody development improve BUBR1 research?

Emerging technologies offer promising avenues for advancing BUBR1 antibody development:

• AI-driven antibody design:

  • RFdiffusion and similar tools can generate new antibody blueprints unlike any seen during training

  • These approaches can be specialized for building antibody loops—the flexible regions responsible for binding

  • AI models can predict antibody-antigen binding with increasing accuracy

• High-throughput screening approaches:

  • Library-on-library approaches can identify specific interacting pairs

  • Active learning algorithms can reduce experimental costs by starting with small labeled datasets and iteratively expanding them

  • These methods have shown to reduce the number of required antigen mutant variants by up to 35%

• Biophysics-informed modeling:

  • These models can identify different binding modes associated with particular ligands

  • They enable the prediction and generation of specific variants beyond those observed in experiments

  • This approach has applications for creating antibodies with both specific and cross-specific binding properties

• Improved validation technologies:

  • Single-cell imaging technologies can provide higher resolution data on BUBR1 localization

  • Proximity labeling methods can identify previously unknown BUBR1 interaction partners

  • Advanced proteomics can characterize post-translational modifications with greater sensitivity

What experimental approaches can resolve contradictory findings regarding BUBR1 function in different cellular contexts?

Contradictory findings about BUBR1 function may arise from differences in experimental systems, cell types, or methodologies. Several approaches can help resolve these contradictions:

• Standardized experimental systems:

  • Develop common cell line panels with defined genetic backgrounds

  • Standardize protocols for cell synchronization and mitotic arrest

  • Create shared resources of validated BUBR1 antibodies and mutant constructs

• Context-specific analysis:

  • Compare BUBR1 function in normal vs. cancer cells

  • Investigate cell-type specific differences in BUBR1 regulation

  • Examine differences between in vitro and in vivo systems

• Comprehensive domain mapping:

  • Use systematic mutation analysis to define domain-specific functions

  • Map post-translational modification sites and their impact on function

  • Develop domain-specific antibodies to track specific functions

• Integration of multiple methodologies:

  • Combine genetic approaches (CRISPR, RNAi) with biochemical studies

  • Utilize both fixed and live-cell imaging to capture dynamic processes

  • Apply systems biology approaches to model BUBR1 in broader cellular networks

• Replication studies:

  • Independently validate key findings across multiple laboratories

  • Document differences in experimental conditions that may explain disparate results

  • Develop consensus guidelines for BUBR1 research methodologies